

## INVESTOR WEBINAR

### Highlights:

- **Echo IQ will hold an investor webinar at 2:00pm AEST on Monday, 27 May 2024, hosted by Chief Commercial Officer, Mr Deon Strydom**
- **Webinar follows EIQ's formal submission to the US FDA for market clearance of its proprietary AI-backed decision support tool to assist in the detection of aortic stenosis**
- **Webinar presentation will also highlight recently commenced clinical study with leading research group St. Vincent's Institute of Medical Research using EIQ's novel AI solution to detect the risk of heart failure**
- **Additional details to be provided around Company's regulatory, product development and commercialisation pathways**

**Sydney:** Artificial Intelligence and Medical Technology company Echo IQ ("the Company") (ASX:EIQ) is pleased to advise that it will host an investor webinar at 2:00pm AEST on Monday, 27 May 2024 at which Chief Commercial Officer Deon Strydom will provide an update to investors.

The webinar follows the Company's recent formal submission to the US Food and Drug Administration ("FDA") for market clearance of its proprietary artificial intelligence ("AI") backed decision support tool to assist in the detection of aortic stenosis ("EchoSolv™ AS"). The outcome of the application is expected to be received within 90 days, making EchoSolv well-advanced on its pathway to a commercial outcome.

During the webinar, Mr Strydom will also provide an update on several commercialisation initiatives with potential counterparties in the USA, ahead of the EchoIQ executive team's upcoming visit to the US where discussions are expected to further advance.

The presentation will also include further details on the formal commencement of a clinical study – carried out in partnership with leading research group St. Vincent's Institute of Medical Research – using Echo IQ's novel AI solution to detect the risk of heart failure.

The Company will lodge an updated investor presentation today, which will be used during the webinar.

The briefing will be followed by a Q&A session. Questions can be submitted now to [sam.jacobs@sdir.com.au](mailto:sam.jacobs@sdir.com.au) or in written form during the webinar.

Anyone wishing to attend the webinar must register using the below link.

### **Webinar Details**

**Date and time:** 2:00pm AEST (12:00pm AWST) on Monday, 27 May 2024

**Register via:** <https://register.gotowebinar.com/register/1010273504427277909>

- ENDS -

**Authorised for release by the Board of Directors of Echo IQ Limited.**

**Media Enquiries:**

Philip Woolff, Chief Operating Officer  
[philip.woolff@echoiq.ai](mailto:philip.woolff@echoiq.ai) / [marketing@echoiq.ai](mailto:marketing@echoiq.ai) / +61 (0)490 030 620

**Investor Enquiries:**

Andrew Grover, Executive Chair  
[Andrew.grover@echoiq.ai](mailto:Andrew.grover@echoiq.ai) / [investor@echoiq.ai](mailto:investor@echoiq.ai)

**ABOUT ECHO IQ**

Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology. The company is based in Sydney, Australia.